TNM001

BIOLOGICAL3 trials

Sponsors

Zhuhai Trinomab Pharmaceutical Co., Ltd.

Conditions

Respiratory Syncytial Virus Infections

Phase 1

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

CompletedNCT05630573

Zhuhai Trinomab Pharmaceutical Co., Ltd.Respiratory Syncytial Virus Infections

Start: 2022-10-25End: 2023-06-30Updated: 2024-06-28

Phase 2

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

CompletedNCT06083623

Zhuhai Trinomab Pharmaceutical Co., Ltd.Respiratory Syncytial Virus Infections

Start: 2023-09-11End: 2025-11-05Updated: 2026-03-05

Phase 3

A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants

CompletedNCT06710925

Zhuhai Trinomab Pharmaceutical Co., Ltd.Respiratory Syncytial Virus Infections

Start: 2024-11-28End: 2025-12-14Updated: 2026-03-05